Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer

Feb 07 2019

• By Emily Hayes

Doctor with Mammography - Image

Related Content

Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups

Jul 18 2017

MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo

Oct 23 2015

Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

Oct 26 2017

Related Companies

MacroGenics, Inc.

Roche Holding AG

Zai Lab Ltd.

University of California San Francisco

Puma Biotechnology, Inc.

Merck & Co., Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window